Precigen Stock Gets Stronger EPS Estimate from HC Wainwright

Precigen, Inc. (NASDAQ:PGEN – Free Report) – Equities researchers at HC Wainwright lifted their Q4 2026 EPS estimates for Precigen in a note issued to investors on Thursday, November 5th. HC Wainwright analyst S. Ramakanth now expects that the biotechnology company will post earnings per share of $0.11 for the quarter, up from their previous forecast of $0.06. HC Wainwright has a “Buy” rating and a $18.00 price objective on the stock. The consensus estimate for Precigen’s current full-year earnings is $0.27 per share. HC Wainwright also issued estimates for Precigen’s Q1 2027 earnings at $0.13 EPS, Q2 2027 earnings at $0.15 EPS, Q3 2027 earnings at $0.17 EPS and Q4 2027 earnings at $0.19 EPS.

Precigen (NASDAQ:PGEN – Get Free Report) last announced its earnings results on Wednesday, November 4th. The biotechnology company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.02. The business had revenue of $74.15 million for the quarter, compared to analyst estimates of $71.55 million. Precigen had a net margin of 15.55% and a return on equity of 57.93%. The company’s revenue for the quarter was up 2437.6% compared to the same quarter last year. During the same quarter last year, the business earned ($1.06) earnings per share.

Several other equities research analysts have also recently issued reports on PGEN. Zacks Research cut Precigen from a “strong-buy” rating to a “hold” rating in a report on Monday, October 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Precigen in a report on Thursday, October 15th. B. Riley Financial started coverage on Precigen in a report on Friday, September 25th. They set a “buy” rating and a $12.00 target price for the company. Citizens Jmp raised their target price on Precigen from $11.00 to $12.00 and gave the company a “market outperform” rating in a research report on Thursday. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Precigen in a research note on Thursday. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Precigen currently has a consensus rating of “Moderate Buy” and an average target price of $13.50.

View Our Latest Analysis on PGEN

Precigen Stock Up 5.9%

PGEN opened at $4.47 on Friday. The company has a market cap of $1.59 billion, a PE ratio of 44.70 and a beta of 1.01. Precigen has a twelve month low of $3.04 and a twelve month high of $8.98. The company has a 50-day moving average price of $6.98 and a 200 day moving average price of $5.28. The company has a quick ratio of 3.89, a current ratio of 5.58 and a debt-to-equity ratio of 1.12.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Commonwealth Equity Services LLC raised its position in shares of Precigen by 5.9% during the 3rd quarter. Commonwealth Equity Services LLC now owns 52,532 shares of the biotechnology company’s stock valued at $450,000 after buying an additional 2,909 shares during the period. Cetera Investment Advisers grew its position in Precigen by 0.9% in the first quarter. Cetera Investment Advisers now owns 374,514 shares of the biotechnology company’s stock worth $1,449,000 after acquiring an additional 3,250 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al grew its position in Precigen by 10.6% in the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 44,000 shares of the biotechnology company’s stock worth $377,000 after acquiring an additional 4,200 shares during the period. Arizona State Retirement System increased its stake in Precigen by 10.5% during the second quarter. Arizona State Retirement System now owns 53,713 shares of the biotechnology company’s stock worth $306,000 after acquiring an additional 5,086 shares during the last quarter. Finally, Carolina Wealth Advisors LLC acquired a new stake in Precigen during the third quarter worth $46,000. 33.51% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Precigen

In other news, COO Rutul Shah sold 15,342 shares of the stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $7.50, for a total value of $115,065.00. Following the completion of the sale, the chief operating officer directly owned 468,865 shares in the company, valued at $3,516,487.50. This represents a 3.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jeffrey Kindler sold 185,000 shares of the firm’s stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $7.44, for a total transaction of $1,376,400.00. Following the completion of the transaction, the director directly owned 17,100 shares in the company, valued at approximately $127,224. This represents a 91.54% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 235,000 shares of company stock valued at $1,751,400 over the last quarter. Company insiders own 41.40% of the company’s stock.

Trending Headlines about Precigen

Here are the key news stories impacting Precigen this week:

  • Positive Sentiment: HC Wainwright raised its earnings forecasts for Precigen across Q4 2026 and each quarter of 2027, while maintaining a Buy rating and an $18 price target. HC Wainwright estimates and rating
  • Positive Sentiment: Citizens JMP raised its price target from $11 to $12 and reiterated a Market Outperform rating, adding to the bullish analyst outlook. Citizens JMP price target
  • Positive Sentiment: Precigen’s Q3 revenue of $74.1 million topped the cited FactSet estimate of $71.5 million. The reported $0.08 per-share earnings beat some estimates but fell short of the higher Zacks consensus, making the earnings picture mixed. Q3 revenue results
  • Negative Sentiment: A valuation analysis argues that PGEN may already be fully priced based on current earnings, which could limit further upside if future growth does not meet expectations. Precigen valuation analysis

About Precigen

(Get Free Report)

Precigen, Inc is a clinical-stage biotechnology company focused on developing gene and cell therapies for cancer and serious diseases. The company uses its proprietary UltraCAR-T, AdenoVerse, and other gene-engineering platforms to design potential treatments intended to improve the targeting, persistence, and manufacturing of therapeutic cells and genetic medicines.

Precigen’s pipeline has included PRGN-2012, an investigational immunotherapy based on a gorilla adenovector for recurrent respiratory papillomatosis, as well as PRGN-2001, an investigational HPV-targeted immunotherapy.

Read More

Earnings History and Estimates for Precigen (NASDAQ:PGEN)

Receive News & Ratings for Precigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precigen and related companies with MarketBeat.com's FREE daily email newsletter.